These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
11. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175 [No Abstract] [Full Text] [Related]
12. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055 [No Abstract] [Full Text] [Related]
14. Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. De Falco V; Napolitano S; Franco R; Zito Marino F; Formisano L; Esposito D; Suarato G; Napolitano R; Esposito A; Caraglia F; Giugliano MC; Cioli E; Famiglietti V; Bianco R; Argenziano G; Ronchi A; Ciardiello D; Nardone V; D'Ippolito E; Del Tufo S; Ciardiello F; Troiani T Oncoimmunology; 2024; 13(1):2388315. PubMed ID: 39206096 [TBL] [Abstract][Full Text] [Related]
15. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma. Lee A; Duggan S; Deeks ED Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208 [TBL] [Abstract][Full Text] [Related]
16. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Lebas E; Marchal N; Rorive A; Nikkels AF Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680 [TBL] [Abstract][Full Text] [Related]
17. Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma. Mallardo D; Sparano F; Vitale MG; Trojaniello C; Fordellone M; Cioli E; Esposito A; Festino L; Mallardo M; Vanella V; Facchini BA; De Filippi R; Meinardi P; Ottaviano M; Caracò C; Simeone E; Ascierto PA Cancer Immunol Immunother; 2024 Jun; 73(8):160. PubMed ID: 38850335 [TBL] [Abstract][Full Text] [Related]
18. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Ahmed SR; Petersen E; Patel R; Migden MR Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530 [No Abstract] [Full Text] [Related]